Anticoagulation for Moderate to Severe Rheumatic Mitral Stenosis

Introduction to Anticoagulation Recommendations

The European Society of Cardiology recommends vitamin K antagonist (warfarin) with a target INR of 2.0-3.0 for all patients with moderate to severe rheumatic mitral stenosis and atrial fibrillation, and should be strongly considered even in sinus rhythm when specific high-risk features are present 1, 2

Patients with Atrial Fibrillation

Anticoagulation with warfarin (INR 2.0-3.0) is mandatory for all patients with rheumatic mitral stenosis and atrial fibrillation, regardless of stenosis severity 1, 2
Direct oral anticoagulants (DOACs) are contraindicated in moderate to severe mitral stenosis 3, 4, 5

Patients in Sinus Rhythm

The European Society of Cardiology recommends anticoagulation with warfarin (INR 2.0-3.0) when high-risk features are present, such as history of systemic thromboembolism or left atrial thrombus visualized on echocardiography 1, 2, 6
Anticoagulation with warfarin (INR 2.0-3.0) should be considered in patients with left atrial diameter ≥55 mm or dense spontaneous echo contrast in the left atrium 7, 6, 8

Practical Anticoagulation Management

The American Heart Association recommends starting warfarin at 2-5 mg daily and avoiding loading doses to minimize hemorrhagic complications 4
The European Society of Cardiology recommends performing transesophageal echocardiography immediately before percutaneous mitral balloon commissurotomy (PMBC) to exclude left atrial thrombus 7
The American Heart Association recommends checking INR weekly during initiation and monthly once stable in therapeutic range, and reassessing renal and hepatic function at least annually 4

Target INR

The European Society of Cardiology recommends a standard target INR of 2.5 (range 2.0-3.0) for patients with moderate to severe rheumatic mitral stenosis 1, 7

Special Populations

The European Society of Cardiology recommends considering bioprosthetic valve rather than mechanical for women of childbearing age to avoid hazards of anticoagulation during pregnancy 1
The American College of Cardiology recommends warfarin with target INR 3.0 (range 2.5-3.5) plus aspirin 75-100 mg daily indefinitely for patients with mechanical mitral valve 9

Prevention Strategy for Severe Mitral Stenosis and Stroke

Primary Anticoagulation Strategy

The American Heart Association/American Stroke Association recommends warfarin anticoagulation with a target INR of 2.5 (range 2.0-3.0) for patients with severe mitral stenosis and a history of stroke, regardless of whether atrial fibrillation is present 10
Warfarin is the only recommended anticoagulant for moderate to severe mitral stenosis, according to the 2021 AHA/ASA guidelines, to reduce the risk of recurrent stroke or TIA 11, 12

Critical Contraindications

The American Heart Association/American Stroke Association gives direct oral anticoagulants (DOACs) a Class 3: Harm recommendation in patients with mechanical heart valves, and DOACs are absolutely contraindicated in moderate to severe mitral stenosis 11, 12

Role of Antiplatelet Therapy

Antiplatelet therapy alone is insufficient for stroke prevention in severe mitral stenosis, according to the AHA/ASA guidelines 12

Atrial Fibrillation Considerations

If atrial fibrillation is present, warfarin anticoagulation is absolutely mandatory, with the same INR target of 2.0-3.0 applying whether AF is present or absent 10

Anticoagulation Strategies in Mitral Stenosis

Introduction to Anticoagulation

Mitral stenosis increases stroke risk 20-fold compared to patients in sinus rhythm, according to the American College of Cardiology 13

Bridging Therapy with Enoxaparin

Enoxaparin serves as temporary bridging in specific perioperative scenarios, including high-risk patients with mechanical valve in mitral position, recent thrombosis or embolism, or three or more risk factors, as recommended by the American Heart Association 14
The bridging protocol involves using enoxaparin 1 mg/kg subcutaneously every 12 hours when INR falls below 2.0 before high-risk procedures, as suggested by the American Heart Association 14

Dosing Adjustments for Enoxaparin

For elderly patients (≥75 years), the recommended dose is 0.75 mg/kg subcutaneously every 12 hours without IV bolus, according to the American Heart Association 15
For patients with severe renal impairment (CrCl <30 mL/min), the dose should be reduced to 1 mg/kg subcutaneously once daily, or preferably switched to unfractionated heparin with aPTT monitoring, as recommended by the American Heart Association 15

Contraindications and Precautions

Direct oral anticoagulants (DOACs) are contraindicated in moderate to severe mitral stenosis, according to the American College of Cardiology 13
Switching between enoxaparin and unfractionated heparin during the same treatment course increases bleeding risk, as warned by the American Heart Association 15

NOAC Contraindication and Warfarin Management in Rheumatic Mitral Stenosis

Contraindication of Direct Oral Anticoagulants

Guideline Recommendations (AHA/ACC/HRS)

Warfarin Use (when NOACs are prohibited)

Monitoring Requirements for Warfarin

Warfarin Anticoagulation in Native Valvular Heart Disease: Indications, Targets, and Contraindications

Absolute Indications – Immediate Initiation (Grade 1A)

Warfarin (target INR 2.5, therapeutic range 2.0–3.0) must be started immediately in any patient with native valvular heart disease who has atrial fibrillation, a documented left‑atrial thrombus, or a prior systemic embolic event, because these are absolute indications for anticoagulation. [17][18]
In rheumatic mitral valve disease, the presence of atrial fibrillation (regardless of mitral stenosis severity or left‑atrial size) mandates immediate warfarin therapy. [17][19][20][21]
A left‑atrial thrombus identified on echocardiography is an absolute indication for immediate warfarin initiation. [17][20]18
A history of systemic embolism or stroke, even if the patient is currently in sinus rhythm, requires immediate warfarin therapy. [17][19]18

Consideration in Sinus Rhythm with Enlarged Left Atrium (Grade 2C)

In patients with rheumatic mitral valve disease who are in sinus rhythm, warfarin may be considered when the left‑atrial diameter is ≥ 55 mm on echocardiography, despite the absence of atrial fibrillation. [17][18]
The presence of dense spontaneous echo contrast in the left atrium is another factor supporting consideration of warfarin in sinus‑rhythm patients. 18

Target INR and Monitoring

The recommended target INR for all native valve disease patients on warfarin is 2.5 (acceptable range 2.0–3.0). [17][18]

Direct Oral Anticoagulants (DOACs) – Absolute Contraindication (Class III: Harm)

DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are absolutely contraindicated in patients with moderate‑to‑severe rheumatic mitral stenosis. 21
DOACs are also contraindicated in any patient with rheumatic valve disease who has atrial fibrillation. 21
The contraindication is based on systematic exclusion of these patients from landmark DOAC trials and the RE‑ALIGN trial, which demonstrated excess thromboembolism and bleeding with dabigatran in valve disease. 21

Pre‑Procedural Management Before Percutaneous Mitral Balloon Valvotomy (PMBV)

If a left‑atrial thrombus is detected on pre‑procedure transesophageal echocardiography, the PMBV should be postponed and warfarin initiated with a higher target INR of 3.0 (range 2.5–3.5). [17][18]
Approximately 62 % of left‑atrial thrombi resolve within six months of therapeutic warfarin therapy. 18
Predictors of thrombus resolution include NYHA functional class II or better, thrombus size < 1.6 cm², and maintaining an INR ≥ 2.5. 18
If the thrombus persists despite adequate anticoagulation, PMBV should not be performed. [17][18]

Situations Where Warfarin Is Not Indicated

Patients with rheumatic mitral valve disease in sinus rhythm, left‑atrial diameter < 55 mm, and no prior embolism or thrombus do not require warfarin (Grade 2C suggests no antithrombotic therapy). [17][18]
Asymptomatic patent foramen ovale or atrial septal aneurysm without a history of cryptogenic stroke does not merit warfarin therapy. 17
In infective endocarditis, anticoagulation is contraindicated unless another independent indication exists. 17

Definitive Recommendation

Warfarin remains the only acceptable oral anticoagulant for patients with rheumatic valve disease; DOACs should never be used in this population. 21

Anticoagulation in Atrial Fibrillation with Moderate‑to‑Severe Mitral Stenosis

Guideline Recommendations

ESC 2024 (Class I) recommends direct oral anticoagulants (DOACs) over vitamin‑K antagonists for stroke prevention in atrial fibrillation, except in patients with mechanical heart valves or moderate‑to‑severe mitral stenosis; in these groups DOACs are contraindicated. 22
AHA/ACC/HRS 2019 (Class III Harm) explicitly contraindicates DOAC use in patients with moderate‑to‑severe mitral stenosis or mechanical heart valves, mandating warfarin therapy. 23, 24
Both the 2024 ESC and 2019 AHA/ACC/HRS guidelines state that DOACs are recommended for stroke prevention in atrial fibrillation except in the presence of moderate‑to‑severe mitral stenosis or mechanical prostheses. 22, 23, 25

Warfarin as the Sole Anticoagulant

Warfarin with a target INR of 2.5 (acceptable range 2.0–3.0) is mandatory for all patients with atrial fibrillation and moderate‑to‑severe mitral stenosis. 22, 23

Monitoring and Management of Warfarin

During warfarin initiation, weekly INR measurements are required until the therapeutic range is achieved. 23, 24
Once a stable INR is established, monthly INR checks are recommended to maintain control. 23, 24
An annual reassessment of renal and hepatic function should be performed to ensure continued safety of warfarin therapy. 23, 24

Clinical Decision Rules

The CHA₂DS₂‑VASc score should not be used alone to select anticoagulant type; the presence of moderate‑to‑severe mitral stenosis automatically mandates warfarin regardless of stroke‑risk score. 22, 23
“Non‑valvular atrial fibrillation” is defined as atrial fibrillation without moderate‑to‑severe mitral stenosis or mechanical heart valves; patients with other valve lesions may still be eligible for DOACs. 24